Datapoint: J&J Scores Label Expansion for Stelara

The FDA this week expanded Johnson and Johnson’s Stelara’s psoriatic arthritis label, expanding its use to pediatric patients aged six and older. Stelara first launched in 2009 as a therapy for moderate to severe plaque psoriasis, and has since expanded across the immunology space. For the treatment of psoriatic arthritis, virtually all insured lives (99%) have covered or better access to Stelara under the pharmacy benefit. About 40% of those lives have preferred access to Stelara, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 8/3/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: New Startup Insurer to Expand to Six More States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: FDA Approves Lilly’s Interchangeable Insulin

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today